14 October 2021

Function or Sequence Antibody Patents in Japan after Baxalta v ChugaiAmgen v Sanofi

The issue of how to define an antibody for patent protection purposes has been fiercely debated worldwide. Should it be defined by function, or its amino acid sequence? Takanori Abe will discuss the first antibody patent infringement lawsuit in Japan, Baxalta v Genentech & Chugai Pharmaceuticals, and the second, Amgen v Sanofi. Abe’s insights on the case are informed by his previous experience representing Baxalta in Japan.

Join us as Abe explains the attitude of Japanese courts to these cases. In addition he will explain a strategy for obtaining antibody claims and freedom to operate assessments after these two cases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk